US 12,454,560 B2
Colon and pancreas cancer peptidomimetics
Xue-Ping Wang, Port Washington, NY (US)
Assigned to Precision Biologics, Inc., Bethesda, MD (US)
Filed by Precision Biologics, Inc., Bethesda, MD (US)
Filed on Jun. 24, 2021, as Appl. No. 17/356,605.
Application 17/356,605 is a division of application No. 16/697,231, filed on Nov. 27, 2019, granted, now 11,078,245.
Application 16/697,231 is a division of application No. 15/633,184, filed on Jun. 26, 2017, granted, now 10,533,040, issued on Jan. 14, 2020.
Application 15/633,184 is a division of application No. 14/725,477, filed on May 29, 2015, granted, now 9,718,866, issued on Aug. 1, 2017.
Application 14/725,477 is a division of application No. 13/825,717, granted, now 9,068,014, issued on Jun. 30, 2015, previously published as PCT/US2011/053064, filed on Sep. 23, 2011.
Application 13/825,717 is a continuation in part of application No. PCT/US2011/041502, filed on Jun. 22, 2011.
Claims priority of provisional application 61/385,587, filed on Sep. 23, 2010.
Claims priority of provisional application 61/407,112, filed on Oct. 27, 2010.
Claims priority of provisional application 61/435,176, filed on Jan. 21, 2011.
Claims priority of provisional application 61/435,163, filed on Jan. 21, 2011.
Claims priority of provisional application 61/467,896, filed on Mar. 25, 2011.
Prior Publication US 2021/0395321 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/64 (2017.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01)
CPC C07K 14/4727 (2013.01) [A61K 39/0011 (2013.01); A61K 45/06 (2013.01); A61K 47/64 (2017.08); A61K 47/643 (2017.08); A61K 47/645 (2017.08); A61K 47/646 (2017.08); C07K 14/4748 (2013.01); C07K 16/3092 (2013.01); G01N 33/57419 (2013.01); G01N 33/57438 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/732 (2013.01); C07K 2319/00 (2013.01); G01N 2333/4725 (2013.01)] 8 Claims
 
1. A method of producing an antibody that binds to an MUC5AC epitope which comprises a polypeptide which is at least 80% identical to the amino acid sequence of FPEDYFRYTNQK (SEQ ID NO: 4); SLPDDWFRYINY (SEQ ID NO: 5); SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 20, or SEQ ID NO: 24; which method comprises
(i) immunizing a non-human animal with a polypeptide which comprises a polypeptide which is at least 80% identical to the amino acid sequence of FPEDYFRYTNQK (SEQ ID NO: 4; SLPDDWFRYINY (SEQ ID NO: 5); SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 20, or SEQ ID NO: 24; and
(ii) selecting for one or more antibodies which specifically bind to said polypeptide.